<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272541</url>
  </required_header>
  <id_info>
    <org_study_id>Psychoeducation for SMD</org_study_id>
    <nct_id>NCT04272541</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Psychoeducation Program in Patients With Severe Mental Disorder</brief_title>
  <official_title>Effectiveness of a Psychoeducation Program on Metabolic Syndrome, Cardiovascular Risk, Independency and Psychopatology in Patients With Severe Mental Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Granada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Severe Mental Disorder (SMD) show a life expectancy of 13 to 30 years lower
      than the general population. Among the factors that determine this expectancy are
      cardiovascular risk and the metabolic syndrome. The objective of the present study will be to
      evaluate the effectiveness of a rehabilitative intervention comprinsing a psychopharmacology
      and psychoeducation program on cardiovascular risk, metabolic syndrome, independency for
      activities of daily living and psychopathological symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be selected sixty patients diagnosed with SMD from a community Mental Health Unit
      from Spain. It will be implemented a intervention program consisted of psychopharmacology +
      psychoeducation on healthy living habits during three months. The patients will be evaluated
      at the beginning, at three months and at six months follow-up for weight, waist
      circumference, waist-hip ratio, body mass index, cardiovascular risk, independency and
      psychopathology.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">February 20, 2020</start_date>
  <completion_date type="Anticipated">November 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight</measure>
    <time_frame>Change from Baseline in weight at 3 and 6 months</time_frame>
    <description>This measurement registers weight in Kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>Change from Baseline in waist circumference at 3 and 6 months</time_frame>
    <description>This measurement registers waist circumference in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist-hip ratio</measure>
    <time_frame>Change from Baseline in waist-hip ratio at 3 and 6 months</time_frame>
    <description>Waist-hip ratio will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham scale</measure>
    <time_frame>Change from Baseline in Framingham scale at 3 and 6 months</time_frame>
    <description>The Framingham Risk Score is a gender-specific algorithm used to estimate the 10-year cardiovascular risk of an individual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assesment of funtioning Scale</measure>
    <time_frame>Change from Baseline in Global Assesment of funtioning Scale at 3 and 6 months</time_frame>
    <description>This scale evaluates psychological, social, and occupational functioning dimensions on a hypothetical continuum of mental health-illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANNS</measure>
    <time_frame>Change from Baseline in PANNS at 3 and 6 months</time_frame>
    <description>The Positive and Negative Syndrome Scale for mental disorder</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Mental Health Disorder</condition>
  <condition>Healthy Lifestyle</condition>
  <arm_group>
    <arm_group_label>Psychopharmacology + psychoeducation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention program consisted of psychopharmacology + individual psychoeducation (individual treatment including learning of Healthy Lifestyle). This program will be implemented for three months, allocated in several sesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention program consisted of psychopharmacology (standard intervention in mental health services). This program will be implemented for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychopharmacology + psychoeducation intervention</intervention_name>
    <description>Intervention program consisted of psychopharmacology + psychoeducation. This will be executed during 3 months, distribuited in several sessions.</description>
    <arm_group_label>Psychopharmacology + psychoeducation</arm_group_label>
    <other_name>Mixed treatment program</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psychopharmacology intervention</intervention_name>
    <description>Intervention program consisted of psychopharmacology. This will be executed during 3 months.</description>
    <arm_group_label>Habitual intervention</arm_group_label>
    <other_name>Standard intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 40 years old,

          -  A body mass index higher than 30

          -  Psychopathologically stabilized

        Exclusion Criteria:

          -  Cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Manuel Pérez Mármol, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Physiotherapy. Faculty of Health Sciences, University of Granada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>José Manuel Pérez Mármol</name>
      <address>
        <city>Córdoba</city>
        <zip>18007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Granada</investigator_affiliation>
    <investigator_full_name>José Manuel Pérez Mármol</investigator_full_name>
    <investigator_title>José Manuel Pérez Mármol</investigator_title>
  </responsible_party>
  <keyword>cardiovascular risk</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>independency</keyword>
  <keyword>psychopathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

